Press Release Jan 23 2026
Filed with NSE · · 5 pages · English
Summary by 6ix AI
The One India business achieved a strong growth rate, while the North America segment reported significant revenue figures. The company also noted substantial investments in research and development, reflecting its commitment to future growth and product development. Overall, Cipla's financial performance indicates resilience despite challenges in certain product sales, with a focus on expanding its market presence.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Cipla
- Cipla USA Strengthens Lung Leadership with Community Wellness Initiatives
- Press Release Oct 30 2025
- Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles
- Press Release Jul 25 2025
- Press Release May 13 2025
Later from Cipla
- Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
- Cipla strengthens US portfolio with the launch of generic Saxenda for weight management therapy
- Cipla strengthens US portfolio with the launch of generic Saxenda(R) (Liraglutide Injection) for weight management therapy
- Cipla Expands U.S. Respiratory Portfolio with Approval of Nintedanib Capsules (100mg & 150mg) for Idiopathic Pulmonary Fibrosis
- Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
Follow Cipla into a list and get an email when it puts out news.
Follow Cipla